PB 129 of 2023

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023
(No. 10)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 21 December 2023

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

(1)           This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 10).

(2)           This instrument may also be cited as PB 129 of 2023.

2 Commencement

(1)           Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)           Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

[1]           Schedule 1, after entry for Acalabrutinib in the form Tablet 100 mg [Maximum Quantity: 56; Number of Repeats: 5]

insert:

[2]           Schedule 1, entry for Moxonidine in the form Tablet 400 micrograms

omit:

[3]           Schedule 1, entry for Nicorandil in the form Tablets 10 mg, 60

omit:

[4]           Schedule 1, entry for Nicorandil in the form Tablets 20 mg, 60

omit:

[5]           Schedule 1, entry for Pravastatin

substitute:

[6]           Schedule 2, after entry for Moxonidine in the form Tablet 200 micrograms

insert:

[7]           Schedule 2, after entry for Nebivolol in the form Tablet 10 mg (as hydrochloride)

insert: